AI English summary of an SEC filing — figures as filed
Baxter International BAXBaxter said net income attributable to Baxter stockholders for the 3 months ended June 30, 2025 was $91 million, or $0.18 per diluted share, compared to $(314) million in the prior year period. Special items adversely impacted this amount by $185 million.
Key points
AI summaryBaxter said net income attributable to Baxter stockholders for the 3 months ended June 30, 2025 was $91 million, or $0.18 per diluted share, compared to $(314) million in the prior year period. Special items adversely impacted this amount by $185 million.
The company completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for an aggregate purchase price of $3.80 billion in cash and received net after-tax proceeds of approximately $3.3 billion. As of June 30, 2025, it repaid $3.81 billion of short- and long-term indebtedness.
Baxter initiated a voluntary correction for the Novum IQ Large Volume pump on April 24, 2025, which the FDA classified as a Class I recall. The company elected to temporarily stop distributing the Novum LVP in the U.S. and Canada in July 2025, except in the case of medical necessity. A reserve for the potential obligation related to the Novum LVP recorded in Q2 is not material to financial results, the company said.
Baxter said operating cash flows from continuing operations for the 6 months ended June 30, 2025 were $118 million, capital expenditures were $262 million, and cash and cash equivalents as of June 30, 2025 were $1.69 billion.
Key figures
Quarter ended June 30, 2025
- Revenue
- $2.8B
- Operating income
- $191M
- Net income
- $91M
- EPS
- $0.18
- Gross profit
- $991M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 2025 Net Income $91 million
Baxter said net income attributable to Baxter stockholders for the 3 months ended June 30, 2025 was $91 million, or $0.18 per diluted share, compared to $(314) million in the prior year period. Special items adversely impacted this amount by $185 million.
Source · Based on the MD&A text of the filing
Sale of Kidney Care Business and Debt Repayment
The company completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for an aggregate purchase price of $3.80 billion in cash and received net after-tax proceeds of approximately $3.3 billion. As of June 30, 2025, it repaid $3.81 billion of short- and long-term indebtedness.
Source · Based on the MD&A text of the filing
Novum LVP Voluntary Correction
Baxter initiated a voluntary correction for the Novum IQ Large Volume pump on April 24, 2025, which the FDA classified as a Class I recall. The company elected to temporarily stop distributing the Novum LVP in the U.S. and Canada in July 2025, except in the case of medical necessity. A reserve for the potential obligation related to the Novum LVP recorded in Q2 is not material to financial results, the company said.
Source · Based on the MD&A text of the filing
6-Month Cash Flows and Liquidity
Baxter said operating cash flows from continuing operations for the 6 months ended June 30, 2025 were $118 million, capital expenditures were $262 million, and cash and cash equivalents as of June 30, 2025 were $1.69 billion.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…